1 / 11

Heterogeneity and Comparative Effectiveness: Implications for Studies, Reviews, and Policy

Heterogeneity and Comparative Effectiveness: Implications for Studies, Reviews, and Policy . David Atkins, MD, MPH Health Services Research and Development Quality Enhancement Research Initiative Dept. of Veterans Affairs.

phiala
Télécharger la présentation

Heterogeneity and Comparative Effectiveness: Implications for Studies, Reviews, and Policy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Heterogeneity and Comparative Effectiveness: Implications for Studies, Reviews, and Policy David Atkins, MD, MPH Health Services Research and Development Quality Enhancement Research Initiative Dept. of Veterans Affairs

  2. Session Overview:How to Examine for Heterogeneity and Its Implications • Within an individual study • Within a systematic review or meta-analysis • In Policy Decisions • Conclusions

  3. Heterogeneity of treatment effect • Non-random variation in direction or magnitude of individual treatment effects within a population • May be due to factors specific to patient, provider, environment, or treatment • Also referred to as clinical heterogeneity

  4. “Clinical trials are good experiments but poor surveys.” – N. Longford • From Kravitz et al.. Milbank Q. 2004;82:661-687

  5. Heterogeneity vs. Applicability • HTE – How great is variation in the treatment effect for individuals within the study population relative to the “average” effect in that population? • Applicability – Do the results for the study population apply to a specific patient, group or setting of interest (outside of the study)?

  6. “Clinical trials are good experiments but poor surveys.” – N. Longford • From Kravitz et al.. Milbank Q. 2004;82:661-687

  7. Relevance in Policy Debates • Concern that “average” effects don’t apply to individual patients • “Cookbook medicine” • Decisions based on CER that ignore heterogeneity might deny clinicians ability to individualize treatment decisions

  8. Is alendronate (Fosamax) better than calcium and vitamin D to prevent fracture? • What factors might cause heterogeneity in the net benefits of alendronate vs. calcium/vitamin D? • AUDIENCE RESPONSE

  9. Sources of Heterogeneity in Net Benefits of Treatment • Responsiveness to treatment: • E.g., Calcium intake, vitamin D status • Vulnerability to harms • ? Risks from bisphosphonates • Baseline risk in absence of treatment • Age, health status, bone density • Values attached to outcomes • Convenience of regimens

  10. Scenario • 63 year old woman with diabetes and ischemic heart disease, evaluated for cardiac procedure to address increasing exertional chest pain despite optimal medical therapy. She has two-vessel disease with preserved LV function. She is pondering whether to have PCA with stent or bypass.

  11. Question • Is bypass surgery or percutaneous coronary intervention (PCI) superior for treating coronary artery disease? • Does the answer depend on patient or intervention factors (i.e. is there heterogeneity of the treatment effects )?

More Related